NCT04846920View on ClinicalTrials.gov

A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

June 14, 2021

Primary Completion Date

July 21, 2026

Study Completion Date

July 21, 2026

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Belzutifan

40 mg tablet administered orally at a dose of 160 mg, 200 mg, or 120 mg.

Trial Locations (4)

37232

Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 1005), Nashville

48109

University of Michigan ( Site 1006), Ann Arbor

77030

University of Texas MD Anderson Cancer Center-Genitourinary Medical Oncology ( Site 1007), Houston

02215

Beth Israel Deaconess Medical Center ( Site 1002), Boston

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY